ATYR
ATYR clinical trials: aTYR PHARMA INC
Every trial on ClinicalTrials.gov where aTYR PHARMA INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 9
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ATYR on the catalyst calendar · ATYR registry changes
- Primary completion Jun 25, 2025ActualPhase 3NCT05415137Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary SarcoidosisaTyr Pharma, Inc. · Pulmonary SarcoidosisCompletedATYRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2026Sponsor estimatePhase 2NCT05892614Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial...aTyr Pharma, Inc. · Interstitial Lung DiseaseRecruitingATYRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 18, 2017ActualPhase 1/Phase 2NCT02836418Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and...aTyr Pharma, Inc. · Facioscapulohumeral Muscular DystrophyCompletedATYRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 12, 2016ActualPhase 1/Phase 2NCT02603562Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular DystrophyaTyr Pharma, Inc. · Facioscapulohumeral Muscular Dystrophy (FSHD)CompletedATYRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 5, 2016ActualPhase 1/Phase 2NCT02579239Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and...aTyr Pharma, Inc. · Limb-Girdle Muscular DystrophiesCompletedATYRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 23, 2020ActualPhase 2NCT04412668Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19aTyr Pharma, Inc. · SARS-CoV-2 (COVID-19) Severe PneumoniaCompletedATYRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 26, 2016ActualPhase 1/Phase 2NCT02531217Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study ExtensionaTyr Pharma, Inc. · Facioscapulohumeral Muscular DystrophyCompletedATYRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 29, 2021ActualPhase 1/Phase 2NCT03824392Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary SarcoidosisaTyr Pharma, Inc. · Pulmonary SarcoidosisCompletedATYRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2015ActualPhase 1/Phase 2NCT02239224Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular DystrophyaTyr Pharma, Inc. · Facioscapulohumeral Muscular Dystrophy (FSHD)CompletedATYRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2017ActualNo phase registeredNCT01437345A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHDCooperative International Neuromuscular Research Group · Facioscapulohumeral Muscular DystrophyCompletedATYRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner